Pursuing Novel Ideas
Pioneering Innovative Therapies
Board of Directors
David S. Battleman, MD, MSc, MBA
Dr. Battleman is a seasoned healthcare executive with over 15 years of experience, spanning academia, industry and management consulting. Prior to establishing his own consulting firm, TrueNorth Lifesciences, Dr. Battleman served as a senior principal in the Pricing and Market Access (P&MA) practice within IMS Health, a global Fortune 500 company providing lifescience data and consulting services to the pharmaceutical industry.
Prior to joining IMS, Dr. Battleman served as senior director / executive director for Pfizer Pharmaceuticals where he was responsible for developing value-based product strategy and communications across Pfizer's cardiovascular portfolio, ranging from early-stage to marketed products. And within academia, Dr. Battleman was an assistant professor of public health and medicine at Cornell University’s Weill Cornell Medical College. There, Dr. Battleman’s research focused primarily on the areas of quality measurement and value assessment in healthcare and he has published both original research and expert reviews in these areas.
Dr. Battleman holds an M.D. from Weill Cornell Medical College, an M.B.A. from the University of Pennsylvania’s Wharton School of Business, and an M.Sc. in epidemiology from the Harvard School of Public Health. He is also a board-certified internist.
Michael
Chancellor, MD
Dr. Chancellor is internationally recognized as the leader in urinary
bladder treatment and research. Prior to joining Lipella, Dr.
Chancellor was Professor of Urology at the University of Pittsburgh
School of Medicine, and co-founder of Cook Myosite, originator of the
first approved U.S. human urologic stem cell clinical trial. Dr.
Chancellor has been principal investigator of over 75 additional
clinical trials including physician sponsored IND trials. He is the
recipient of over 25 NIH grants, and author of more than 300
peer-reviewed publications. He is consultant and advisory board member
to over a dozen companies including Pfizer, Merck, J&J, Lilly,
AstraZeneca, Allergan, Astellas, P&G and Indevus. Dr.
Chancellor
received his MD from the Medical College of Wisconsin, and completed
his residency and fellowship training at the University of Michigan and
Columbia University.
Jonathan
Kaufman, PhD
Prior to co-founding Lipella, Dr.Kaufman was Vice President and Chief
Science Officer of LaunchCyte LLC, a biotechnology corporate incubator.
At LaunchCyte, Dr. Kaufman was co-founder of Proteopure Inc. and Knopp
Neuroscience Inc.; served as the founding President of Crystalplex
Corp.; served on the Boards of Reaction Biology Corp., Crystalplex
Corp., and Immunetrics Inc.; and served as Secretary of Reaction
BiologyCorp. Prior to joining LaunchCyte, Dr. Kaufman served on the New
Technology Committee in the Chemical Manufacturing Division of Merck
& Co., and also served as a consultant to GlaxoSmithKline in
the
department of bioinformatics. Dr. Kaufman received his MBA in Finance
from the Wharton School, and his PhD in Biophysics from the University
of Pennsylvania School of Medicine.
Tom Petzinger
Tom is founder, Chairman, President and CEO of LaunchCyte LLC, a
development company that creates, seeds, and harvests life sciences
innovations from leading research universities across the U.S.
Currently, LaunchCyte has six life sciences portfolio companies, with a
combined value of approximately $150 million. In addition to leading
LaunchCyte, Tom is Executive Vice President, Business Development &
Public Affairs for Knopp Neurosciences, one of LaunchCyte’s newest
portfolio companies. Tom is a director on the board of all six of
LaunchCyte’s portfolio companies. Prior to founding LaunchCyte, Tom
spent 22 years at The Wall Street Journal, where he served as
Washington economics editor, deputy Washington bureau chief, millennium
editor, and weekly columnist. Tom received his B.S. in Journalism from
Northwestern University, where he was a Richter International Scholar.